Hepatitis c drugs market
Hepatitis C Drugs Market, By Drug Class (NS3/4A Protease Inhibitors, NS5A Inhibitors, NS5B Polymerase Inhibitors, Combination Drugs, others), By Route of Administration (Oral Drugs, Intravenous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
- Jan 2024
- CMI1489
- 151 Pages
- Excel & Pdf
- Pharmaceutical
Summary
The hepatitis C drugs market size is expected to reach US$ 11.39 billion by 2030, from US$ 8.60 billion in 2023, growing at a CAGR of 4.1% during the forecast period. Hepatitis C is a viral infection that causes liver swelling, called inflammation. Hepatitis C can lead to serious liver damage. The hepatitis C virus (HCV) spreads through contact with blood that has the virus in it.
Symptoms of hepatitis C include fever, feeling very tired, loss of appetite, nausea and vomiting, abdominal pain, dark urine, pale feces, joint pain, and jaundice (yellowing of the skin or eyes).
Hepatitis c Drugs Market Regional Insights:
- North America is expected to be the largest market for hepatitis C drugs during the forecast period, accounting for over 40.6% of the market share in 2023 The growth of the market in North America is attributed to increasing product launches
- Europe is expected to be the second-largest market for hepatitis C drugs, accounting for over 27.3% of the market share in 2022. The growth of the market in the region is attributed to increasing inorganic strategies by the market players.
- Asia Pacific is expected to be the fastest-growing market for hepatitis C drugs, growing with a CAGR of over 6.2% during the forecast period. The growth of the market in Asia Pacific is attributed to the increasing prevalence of hepatitis C in the region.
Figure 1. Global Hepatitis C Drugs Market Share (%), by Region, 2023
Analysts’ Views on Global Hepatitis C Drugs Market:
Hepatitis C drugs market is expected to propel over the forecast period due to the increasing prevalence of hepatitis c globally and increasing research and development, and product launches by the market players. Moreover, increasing funding for research and developmental activities is also expected to boost the market growth over the forecast period.
Hepatitis C Drugs Market Drivers:
- Growing Prevalence of Hepatitis C Globally: Increasing prevalence of hepatitis C globally is expected to drive the market growth over the forecast period. For instance, according to the data published by the World Health Organization on July 18, 2023, globally, an estimated 58 billion people have chronic hepatitis c virus infection, with about 1.5 billion new infections occurring per year. There are an estimated 3.2 billion adolescents and children with chronic hepatitis c infections.
- Increasing Government Initiatives: the Ministry of Health & Family Welfare Government of India has initiated the National Viral Hepatitis Control Program, the aim of the program is to combat hepatitis and achieve countrywide elimination of Hepatitis C by 2030.
Hepatitis c drugs market Opportunities:
- Increasing Product Availability in Various Regions: Increasing availability of products globally will increase the yearly revenues of the product, which is expected to propel the market growth over the forecast period. For instance, on July 20, 2023, The Drug Technology Institute (Farmanguinhos) with Oswaldo Cruz Foundation (Fiocruz) signed a technical and scientific cooperation agreement with the Drugs for Neglected Diseases initiative (DNDi) and Pharco Pharmaceuticals in Egypt to request the registration of ravidasvir, a hepatitis C treatment.
Hepatitis C Drugs Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 8.60 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 4.1% | 2030 Value Projection: | US$ 11.39 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Gilead Sciences, AbbVie, Merck & Co, Bristol-Myers Squibb, Johnson & Johnson, F. Hoffmann-La Roche AG, Boehringer Ingelheim, and Achillion Pharmaceuticals |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Hepatitis C Drugs Market Trends:
- Increasing Partnerships among Market Players: Increasing partnerships among the market players will drive the market growth over the forecast period. For instance, on November 12, 2018, AbbVie, a pharmaceutical company, and the Medicines Patent Pool (MPP) entered into a new, royalty-free licensing agreement to accelerate access to AbbVie’s pan-genotypic hepatitis C virus (HCV) treatment glecaprevir/pibrentasvir (G/P) in 99 low- and middle-income countries and territories.
Hepatitis C drugs market Restraints:
- Increasing Adverse Effects: Increasing adverse effects of the products is expected to hinder the market growth over the forecast period. For instance, according to the data published by the U.S. Food and Drug Administration (FDA) on August 28, 2019, the Food and Drug Administration (FDA) received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases of worsening liver function or liver failure.
Market players should focus on the adverse effects causing due to consumption of the drugs products, and work towards minimizing the adverse effects which aid in the market growth over the forecast period.
Recent Developments:
New product launches:
- On December 7, 2021, Zydus Cadila, a pharmaceutical company based in India, launched a generic version of Gilead Sciences’ Hepatitis C drug Sofosbuvir in India under the brand name ‘SoviHep’.
- On September 24, 2018, Gilead Sciences, Inc., a pharmaceutical company, announced the launch of a generic version of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) for hepatitis C treatment.
Acquisition and partnerships:
- On May 31, 2023, The Institute of Drug Technology (Farmanguinhos/Fiocruz) signed a new partnership for the technological transfer of the drug Daclatasvir. This formalization allows expanding access to the drug deemed strategic for the Brazilian Unified Health System (SUS)
Figure 2. Global Hepatitis C drugs market Share (%), by Route of Administration, 2023
Top Companies in Hepatitis C drugs market:
- Gilead Sciences
- AbbVie
- Merck & Co
- Bristol-Myers Squibb
- Johnson & Johnson
- Hoffmann-La Roche AG
- Boehringer Ingelheim
- Achillion Pharmaceuticals
Definition: Hepatitis C is a viral infection that causes liver swelling, called inflammation. Hepatitis C can lead to serious liver damage. The hepatitis C virus (HCV) spreads through contact with blood that has the virus in it.
Few Other Promising Reports in Pharmaceuticals
Table of Content
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Growing Prevalence of Hepatitis C Globally
- Increasing Government Initiatives
- Restraints
- Increasing Adverse Effects
- Opportunities
- Increasing Product Availability in Various Regions
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Market Dynamics
- Hepatitis C Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
- Hepatitis C Drugs Market, By Drug Class, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 – 2030
- Segment Trends
- NS3/4A Protease Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- NS5B Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Combination Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Introduction
- Hepatitis C Drugs Market, By Route of Administration, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2030 (%)
- Y-o-Y Growth Analysis, 2019– 2030
- Segment Trends
- Oral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Introduction
- Hepatitis C Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2030 (%)
- Y-o-Y Growth Analysis, 2019– 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Introduction
- Hepatitis C Drugs Market, By Region, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2023and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2019–2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- China
- Japan
- India
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
- South Africa
- North Africa
- Central Africa
- Introduction
- Competitive Landscape
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Achillion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
- Gilead Sciences
- Section
- Research Methodology
- About us
*Browse 24 market data tables and 28 figures on “Hepatitis C Drugs Market” - Global forecast to 2030
Segmentation
Hepatitis C Drugs Market Segmentation:
- By Drug Class
- NS3/4A Protease Inhibitors
- NS5A Inhibitors
- NS5B Polymerase Inhibitors
- Combination Drugs
- Others
- By Route of Administration
- Oral Drugs
- Intravenous
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Frequently Asked Questions -
What are the key factors hampering the growth of the hepatitis C drugs market?
Increasing adverse effects is expected to hinder the market growth over the forecast period.
What are the major factors driving the market growth?
Growing prevalence of Hepatitis C globally and increasing government initiatives are expected to propel the market growth over the forecast period.
Which is the leading segment in the market?
The leading segment is drug class due to increasing product launches by the market players.
Which are the major players operating in the market?
Gilead Sciences, AbbVie, Merck & Co, Bristol-Myers Squibb, Johnson & Johnson, F. Hoffmann-La Roche AG, Boehringer Ingelheim, and Achillion Pharmaceuticals
Which region will lead the market?
North America will lead the market.
What will be the CAGR of the market?
The CAGR of the market is 4.1%